Abstract Details
|
Nicholas T. Olney, MD
(Providence)
PRESENTER |
No disclosure on file |
| Antje Bischof, MD | Dr. Bischof has nothing to disclose. |
| Howard J. Rosen, MD (UCSF) | Dr. Rosen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly . Dr. Rosen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alector. The institution of Dr. Rosen has received research support from NIH. The institution of Dr. Rosen has received research support from State of CA. Dr. Rosen has a non-compensated relationship as a Consultant with Prevail Therapeutics that is relevant to AAN interests or activities. Dr. Rosen has a non-compensated relationship as a consultant with Alchemab that is relevant to AAN interests or activities. |
| No disclosure on file | |
| William Stern | No disclosure on file |
| Catherine Lomen-Hoerth, MD, PhD, FAAN (UCSF) | Dr. Lomen-Hoerth has nothing to disclose. |
| Bruce L. Miller, MD, FAAN (University of California, San Francisco) | Dr. Miller has nothing to disclose. |
| Roland G. Henry, PhD (University of California, San Francisco) | Dr. Henry has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MEDDAY. Dr. Henry has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Henry has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Henry has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi/Genzyme. |
| No disclosure on file |